创健医疗2024年净利腰斩、增员近两成，董事长钱松弟弟任董事

Core Viewpoint - Chuangjian Medical (NQ873474) reported a significant decline in net profit for the fiscal year 2024, with a year-on-year decrease of 50.84% [1] Financial Performance - The company achieved operating revenue of 288.15 million yuan, a year-on-year increase of 1.82% [2] - The net profit attributable to shareholders was 33.82 million yuan, down 50.84% from the previous year [2] - The net profit after deducting non-recurring gains and losses was 26.77 million yuan, a decrease of 58.04% [2] - Basic earnings per share were 0.81 yuan, down 53.98% compared to 1.76 yuan in the previous year [2] - The weighted average return on equity was 6.31%, compared to 23.55% in the previous year [2] - The gross profit margin for the period was 73.94%, down from 78.17% year-on-year [2] Business Segments - Revenue from terminal products reached 182 million yuan, reflecting a year-on-year growth of 29.95%, although the gross margin decreased to 70.81% [3] - The revenue from the restructured collagen raw material business was 104 million yuan, down 26.23% year-on-year, with a gross margin of 79.24%, a decrease of 2.09% [3] - The decline in performance was attributed to strategic adjustments in product structure and a reduction in sales volume for certain products [3] Employee Statistics - The total number of employees increased to 503, up 18.35% from 425 at the end of the previous year [4]